Trial Profile
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 28 Jun 2023 Planned End Date changed from 14 Feb 2024 to 14 Feb 2025.
- 28 Jun 2023 Planned primary completion date changed from 14 Feb 2024 to 14 Feb 2025.
- 28 Jun 2022 Planned End Date changed from 14 Feb 2023 to 14 Feb 2024.